All vaccinated adults received doses of vaccines developed by Oxford/AstraZeneca, BioNTech/Pfizer, Janssen, or Moderna between January and July 2021. Researchers focused on early outcomes during the first 30 days after SARS-CoV-2 infection and late outcomes after day 31. The number of people infected has increased to 365.

Overall, the team found that the COVID-19 vaccine was “highly effective” in protecting cardiovascular health in adults with SARS-CoV-2 infection. Adults vaccinated against SARS-CoV-2 infection are less likely to experience a variety of cardiovascular and thromboembolic complications compared to unvaccinated adults with SARS-CoV-2 infection. Risk has been “significantly reduced”. This includes significantly reduced short- and long-term risks of heart failure, venous thromboembolism, and arterial thrombosis/thromboembolism. The effects were greatest during the first 30 days after infection.

“In line with previous studies, our findings suggest a potential benefit of vaccination in reducing the risk of thromboembolic and cardiac complications following COVID-19 infection,” the authors wrote. are writing. “We targeted a broader population, estimated risks during both acute and post-acute infection stages, and replicated these using four large independent observational databases. By pooling results across different settings, we have provided up-to-date and robust evidence on this topic.”

Besora et al. added that these findings “highlight another benefit of COVID-19 vaccination,” but said additional research is still needed to learn more about the topic. .

Click here to read the full analysis.